Neuphoria Therapeutics Inc. (NEUP)
| Market Cap | 17.91M -52.7% |
| Revenue (ttm) | 1.17M -92.5% |
| Net Income | -13.45M |
| EPS | -3.06 |
| Shares Out | 5.41M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,748 |
| Open | 3.250 |
| Previous Close | 3.240 |
| Day's Range | 3.250 - 3.420 |
| 52-Week Range | 3.190 - 17.900 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About NEUP
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc. to develop alpha7 recept... [Read more]
Financial Performance
In fiscal year 2026, Neuphoria Therapeutics's revenue was $1.17 million, a decrease of -92.50% compared to the previous year's $15.65 million. Losses were -$13.45 million, 3539.3% more than in 2025.
Financial StatementsNews
Neuphoria Therapeutics Proxy statement: Proxy filing
Neuphoria Therapeutics filed a proxy statement on September 18, 2026, providing details for shareholder voting and corporate governance matters.
Neuphoria Therapeutics Proxy statement: Proxy filing
Neuphoria Therapeutics filed a proxy statement on September 18, 2026, providing details for shareholder voting and corporate governance matters.
Neuphoria Therapeutics Proxy statement: Proxy filing
Neuphoria Therapeutics filed a proxy statement on September 18, 2026, providing details for shareholder voting and corporate governance matters.
Neuphoria Therapeutics Annual report: Q4 2026
Neuphoria Therapeutics has published its Q4 2026 annual report on September 18, 2026.
Neuphoria Therapeutics Proxy statement: Proxy filing
Neuphoria Therapeutics filed a proxy statement on July 24, 2026, providing details for shareholder voting and corporate governance matters.
Neuphoria Therapeutics to be acquired by Scancell
Neuphoria Therapeutics (NEUP) and Scancell Holdings announced an all-share merger in which Scancell will acquire Neuphoria. Upon completion of the transaction, the combined company plans to operate un...
Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing
OXFORD, United Kingdom and BURLINGTON, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP) (“Scancell”) and Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria”) today announ...
Neuphoria Therapeutics confirms merger discussions with Scancell Holdings
Neuphoria Therapeutics (NEUP) issued the following statement in response to an announcement made by London-listed biotechnology company Scancell Holdings: “The Neuphoria Board notes the announcement m...
Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc
Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or ...
Neuphoria Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis downgraded Neuphoria Therapeutics (NEUP) to Neutral from Buy with no price target after the company announced that the Phase 3 AFFIRM-1 trial of BNC210 for…
Neuphoria Therapeutics Quarterly report: Q3 2026
Neuphoria Therapeutics has published its Q3 2026 quarterly earnings report on May 15, 2026.
Neuphoria Therapeutics Quarterly report: Q2 2026
Neuphoria Therapeutics has published its Q2 2026 quarterly earnings report on February 17, 2026.
Neuphoria announces ISS recommends shareholders vote ‘FOR’ director nominees
Neuphoria Therapeutics (NEUP) announced that Institutional Shareholders Services, ISS, a leading independent proxy advisory firm, has issued a report recommending that Neuphoria shareholders vote on t...
Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees
Company Urges Shareholders to Follow ISS' Recommendation and Vote the WHITE Proxy Card BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) ...
Neuphoria Therapeutics Proxy statement: Proxy filing
Neuphoria Therapeutics filed a proxy statement on December 8, 2025, providing details for shareholder voting and corporate governance matters.
Neuphoria Therapeutics price target lowered to $7 from $21 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Neuphoria Therapeutics (NEUP) to $7 from $21 and keeps a Buy rating on the shares. The firm says the company is “caught…
Neuphoria Therapeutics responds to Lynx1’s revised indication of interest
Neuphoria Therapeutics (NEUP) issued the following statement in response to dissident stockholder, Lynx1 Master Fund’s, revised indication of interest to acquire the Company. As previously announced, ...
Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium
Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote “FOR” BOTH of Neuphoria's Nominees on the WHITE Prox...
Neuphoria Therapeutics Proxy statement: Proxy filing
Neuphoria Therapeutics filed a proxy statement on December 4, 2025, providing details for shareholder voting and corporate governance matters.
Neuphoria Therapeutics ‘exposes false narratives’ responding to Lynx1
The company states: “Neuphoria Therapeutics (NEUP) issued the following statements to address what Neuphoria strongly believes is a campaign from Lynx1 Master Fund LP full of deception and distraction...
Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions
BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies...
Neuphoria Therapeutics Proxy statement: Proxy filing
Neuphoria Therapeutics filed a proxy statement on December 1, 2025, providing details for shareholder voting and corporate governance matters.
Neuphoria Therapeutics Proxy statement: Proxy filing
Neuphoria Therapeutics filed a proxy statement on November 25, 2025, providing details for shareholder voting and corporate governance matters.
Neuphoria Therapeutics urges stockholders to vote for company nominees
Neuphoria Therapeutics (NEUP) issued a letter to its stockholders regarding Neuphoria’s 2025 Annual Meeting of Stockholders, which is scheduled to be held on December 12, 2025. The company said, “The…
Neuphoria Therapeutics Inc. Sends Letter to Stockholders
Files Definitive Proxy Statement for 2025 Annual Meeting of Stockholders Urges Stockholders to Vote “FOR” BOTH Neuphoria Therapeutics Nominees on WHITE Proxy Card BURLINGTON, Mass., Nov. 24, 2025 (GLO...